Artificial Intelligence company Diagnos Inc.'s revenue growth curve rapidly accelerating, clients include Novartis and BAYER.

NEW YORK, NY, UNITED STATES, February 10, 2017 /EINPresswire.com/ -- Market Equities Research Group is responsible for the content of this release. DIAGNOS Inc. commercializes technologies combining contextual imaging and traditional data mining thereby improving decision making processes, offering products, services, and solutions to clients in a variety of fields including healthcare and natural resources. The Company is the subject of a Market Equities Research Group Market Bulletin, full copy of which is available from source at http://marketequitiesresearch.com/marketbulletin-adk-feb-2017.htm online.

The Company is executing on a growth strategy that has been several years in the making. DIAGNOS' revenue growth curve is rapidly accelerating, with revenues coming mainly from artificial intelligence application side of the business non-invasively identifying patients at risk of vision loss in the diabetes market. The technology was first used by DIAGNOS successfully in the mining sector, identifying resources, and now after several years of nurturing the application in healthcare, the numbers that affect share price valuation metrics are simply stunning.

DIAGNOS last week filed on SEDAR its Financial Statements and the Management Discussion and Analysis reports, for the three-month and the nine-month periods ended December 31. The Company exceeded its forecast for the year and was positive for the last quarter. The Company's fiscal year end is March 31, 2017, and is forecasting large increases in revenue going forward.

The confirmation last week by DIAGNOS of the Company now operating profitably is a milestone that management had been working towards for years, it came to fruition as a result of a growing pipeline of new business that first bit on pilot programs and saw highly favorable results that only recently have tuned to larger long-term contracts. The recent turn to profitability falls on the heels of yet another successful pilot project for diabetic macular edema and diabetic retinopathy screening with the Mexican Social Security Institute, and news of the start of a pilot project with BAYER Canada. Swiss pharmaceutical giant Novartis is currently DIAGNOS' largest customer. Novartis initially engaging DIAGNOS for a series of pilot 'wellness' programs over the last couple years in various countries, paying DIAGNOS to screen patients.

Doctors and specialists strongly endorse DIAGNOS' technology as large numbers are able to be non-invasively screened that would otherwise not be seen. DIAGNOS has only recently begun to sell its solutions to governments on a cost-reduction approach, signing its first government contract in Mexico.

Supported by a strong growth and recurring revenue model (at risk patients need to be screened yearly), and a low cost growth associated with its artificial intelligence software, we expect shares of DIAGNOS to rise several multiples higher than its current price near-term.

The following additional research links have been identified for further DD on DIAGNOS Inc.:
- DIAGNOS’ corporate website: http://www.DIAGNOS.ca
- Recent Journal review: http://www.technologymarketwatch.com/adk.htm online.

This release may contain forward-looking statements regarding future events that involve risk and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual events or results. Readers are cautioned that not until subject companies actually releases official details themselves should anyone rely on the information presented herein. Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned.

Fredrick William, BA Ec.
Market Equities Research Group
8666209945
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.